• Thu, Jan. 5, 5:47 AM
    • Shareholders at Datalink Corporation (NASDAQ:DTLK) are scheduled to vote at a special meeting on the company's proposed merger with Insight Enterprises. Datalink closed yesterday just a penny above the buyout price of $11.25.
    • There's also an annual meeting for Cantel Medical Corp. (NYSE:CMN) to keep a watch on.
    Thu, Jan. 5, 5:47 AM
  • Dec. 8, 2016, 8:09 AM
    • Cantel Medical (NYSE:CMN): FQ1 EPS of $0.51 beats by $0.06.
    • Revenue of $187.73M (+22.1% Y/Y) beats by $4.28M.
    • Press Release
    Dec. 8, 2016, 8:09 AM
  • Oct. 14, 2016, 10:24 AM
    • Cantel Medical (NYSE:CMN) declares $0.07/share semi-annual dividend, 16.7% increase from prior dividend of $0.06.
    • Forward yield 0.19%
    • Payable Jan. 31; for shareholders of record Jan. 17; ex-div Jan. 12.
    Oct. 14, 2016, 10:24 AM
  • Sep. 29, 2016, 8:46 AM
    • Cantel Medical (CMN) FQ4 results: Revenues: $179M (+18.3%); Operating Income: $25.8M (+16.7%); Net Income: $16.3M (+22.6%); EPS: $0.39 (+21.9%); Non-GAAP EPS: $0.48 (+23.1%).
    • FY2016 results: Revenues: $664.8M (+17.7%); Operating Income: $97.3M (+20.4%); Net Income: $60M (+25.0%); EPS: $1.44 (+25.2%); Non-GAAP EPS: $1.75 (+21.5%); Quick Assets: $28.4M (-10.4%).
    • No guidance given.
    Sep. 29, 2016, 8:46 AM
  • Sep. 29, 2016, 8:01 AM
    • Cantel Medical (NYSE:CMN): FQ4 EPS of $0.48 beats by $0.11.
    • Revenue of $179M (+18.3% Y/Y) beats by $0.42M.
    • Press Release
    Sep. 29, 2016, 8:01 AM
  • Sep. 28, 2016, 5:30 PM
  • Sep. 2, 2016, 7:52 AM
    • Athenahealth (NASDAQ:ATHN) initiated with Hold rating by Stifel Nicolaus.
    • Juno Therapeutics (NASDAQ:JUNO) initiated with Sell rating and $23 (15% downside risk) price target by BTIG Research. Initiated coverage on Kite Pharma (NASDAQ:KITE) with Neutral rating.
    • Gemphire Therapeutics (Pending:GEMP) initiated with Buy rating and $17 (26% upside) price target by Canaccord Genuity. Initiated with Outperform rating and $25 (86% upside) price target by RBC Capital.
    • Galapagos NV (NASDAQ:GLPG) initiated with Buy rating and $64 (18% upside) price target by Janney Capital.
    • Sophiris Bio (NASDAQ:SPHS) initiated with Overweight rating and $7 (138% upside) price target by Piper Jaffray.
    • Cantel Medical (NYSE:CMN) initiated with Buy rating and $83 (9% upside) price target by Benchmark.
    • Recro Pharma (NASDAQ:REPH) initiated with Buy rating and $21 (122% upside) price target by Janney Montgomery Scott.
    • Theravance Biopharma (NASDAQ:TBPH) initiated with Buy rating and $41 (42% upside) price target by Evercore ISI.
    • Intuitive Surgical (NASDAQ:ISRG) initiated with Outperform rating by Raymond James.
    Sep. 2, 2016, 7:52 AM
  • Aug. 26, 2016, 7:15 AM
    • Actinium Pharmaceuticals (NYSEMKT:ATNM) initiated with Buy rating and $5 (194% upside) price target by Roth Capital.
    • Jazz Pharmaceuticals (NASDAQ:JAZZ) initiated with Neutral rating by Janney Montgomery Scott.
    • Cantel Medical (NYSE:CMN) initiated with Hold rating by Needham.
    • Patheon NV (Pending:PTHN) initiated with Outperform rating by William Blair.
    • Caladrius Biosciences (NASDAQ:CLBS) initiated with Buy rating and $6.50 (31% upside) price target by Chardan Capital.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) initiated with Buy rating and $5 (92% upside) price target by Rodman & Renshaw.
    • Rockwell Medical (NASDAQ:RMTI) initiated with Buy rating and $12 (72% upside) price target by BTIG Research.
    • Agios Pharmaceuticals (NASDAQ:AGIO) initiated with Neutral rating by BTIG Research.
    • TRACON Pharmaceuticals (NASDAQ:TCON) initiated with Buy rating and $15 (137% upside) price target by BTIG Research.
    • Ophthotech (NASDAQ:OPHT) initiated with Buy rating and $92 (76% upside) price target by BTIG Research.
    • Merrimack Pharmaceuticals (NASDAQ:MACK) initiated with Neutral rating by BTIG Research.
    • Acceleron Pharma (NASDAQ:XLRN) initiated with Buy rating and $46 (55% upside) price target by BTIG Research.
    Aug. 26, 2016, 7:15 AM | 15 Comments
  • Jun. 16, 2016, 11:34 AM
    • Cantel Medical (NYSE:CMN) declares $0.06/share semi-annual dividend, in line with previous.
    • Forward yield 0.17%
    • Payable July 29; for shareholders of record July 15; ex-div July 13.
    Jun. 16, 2016, 11:34 AM
  • Jun. 8, 2016, 9:59 AM
    • Cantel Medical (CMN +3.5%) FQ3 results: Revenues: $173.7M (+22.8%); Operating Expense: $57.1M (+35.0%); Operating Income: $23.3M (+9.4%); Net Income: $14M (+12.9%); EPS: $0.34 (+13.3%); Non-GAAP EPS: $0.44 (+25.7%); Quick Assets: $25.5M (-19.6%).
    • No guidance given.
    Jun. 8, 2016, 9:59 AM | 1 Comment
  • Jun. 8, 2016, 8:04 AM
    • Cantel Medical (NYSE:CMN): FQ3 EPS of $0.44 beats by $0.08.
    • Revenue of $173.7M (+22.7% Y/Y) beats by $10.54M.
    Jun. 8, 2016, 8:04 AM
  • Jun. 7, 2016, 5:30 PM
    Jun. 7, 2016, 5:30 PM | 3 Comments
  • Mar. 10, 2016, 8:02 AM
    • Cantel Medical (NYSE:CMN): FQ2 EPS of $0.42 beats by $0.08.
    • Revenue of $158.27M (+16.9% Y/Y) beats by $3.76M.
    Mar. 10, 2016, 8:02 AM | 1 Comment
  • Mar. 9, 2016, 5:30 PM
    Mar. 9, 2016, 5:30 PM | 15 Comments
  • Feb. 3, 2016, 11:29 AM
    • Cantel Medical (CMN -0.3%) acquires the Sterility Assurance Monitoring Products division of North American Science Associates (NAMSA) for $13.5M in cash. The group, which generated $5.7M in sales last year, is comprised of a broad suite of biological and chemical indicators that are used to accurately monitor the effectiveness of sterilization processes. Cantel will fold the business into its Crosstex line in its Healthcare Disposables segment.
    • The transaction should be neutral to GAAP earnings and slightly accretive to non-GAAP earnings in fiscal 2016 (year end July 31) and accretive to both afterward. The deal should close in fiscal Q3.
    Feb. 3, 2016, 11:29 AM
  • Dec. 10, 2015, 8:16 AM
    • Cantel Medical (CMN -1.4%) FQ1 results: Revenues: $153.8M (+12.4%); Operating Expense: $47.4M (+14.2%); Operating Income: $23.8M (+25.3%); Net Income: $14.3M (+27.7%); EPS: $0.34 (+25.9%); Non-GAAP EPS: $0.41 (+20.6%); Quick Assets: $31.1M (-1.9%).
    • No guidance given.
    Dec. 10, 2015, 8:16 AM